Quinolone Antibiotics: Resistance and Therapy

References

• Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother. 2003;51(Suppl 1):13–20.
   PubMed Web of Science ®Google Scholar
• Bush NG, Diez-Santos I, Abbott LR, Maxwell A. Quinolones: mechanism, lethality and their contributions to antibiotic resistance. Molecules. 2020;25(23):E5662.
   PubMed Web of Science ®Google Scholar
• Pham TDM, Ziora ZM, Blaskovich MAT. Quinolone antibiotics. MedChemComm. 2019;10(10):1719–1739.
   PubMed Web of Science ®Google Scholar
• Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis. 2001;32(Suppl 1):S9–S15.
   PubMed Web of Science ®Google Scholar
• Gellert M, Mizuuchi K, O’Dea MH, Itoh T, Tomizawa JI. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A. 1977;74(11):4772–4776.
   PubMed Web of Science ®Google Scholar
• Kato J, Nishimura Y, Imamura R, Niki H, Hiraga S, Suzuki H. New topoisomerase essential for chromosome segregation in E. coli. Cell. 1990;63(2):393–404.
   PubMed Web of Science ®Google Scholar
• Sugino A, Peebles CL, Kreuzer KN, Cozzarelli NR. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci U S A. 1977;74(11):4767–4771.
   PubMed Web of Science ®Google Scholar
• Peng H, Marians KJ. Decatenation activity of topoisomerase IV during oriC and pBR322 DNA replication in vitro. Proc Natl Acad Sci U S A. 1993;90(18):8571–8575.
   PubMed Web of Science ®Google Scholar
• Mizuuchi K, Fisher LM, O’Dea MH, Gellert M. DNA gyrase action involves the introduction of transient double-strand breaks into DNA. Proc Natl Acad Sci U S A. 1980;77(4):1847–1851.
   PubMed Web of Science ®Google Scholar
• Kreuzer KN, Cozzarelli NR. Formation and resolution of DNA catenanes by DNA gyrase. Cell. 1980;20(1):245–254.
   PubMed Web of Science ®Google Scholar
• Hiasa H, DiGate RJ, Marians KJ. Decatenating activity of Escherichia coli DNA gyrase and topoisomerases I and III during oriC and pBR322 DNA replication in vitro. J Biol Chem. 1994;269(3):2093–2099.
   PubMed Web of Science ®Google Scholar
• Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002;3(6):430–440.
   PubMed Web of Science ®Google Scholar
• Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997;61(3):377–392.
   PubMed Web of Science ®Google Scholar
• Willmott CJ, Critchlow SE, Eperon IC, Maxwell A. The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. J Mol Biol. 1994;242(4):351–363.
   PubMed Web of Science ®Google Scholar
• Wentzell LM, Maxwell A. The complex of DNA gyrase and quinolone drugs on DNA forms a barrier to the T7 DNA polymerase replication complex. J Mol Biol. 2000;304(5):779–791.
   PubMed Web of Science ®Google Scholar
• Hiasa H, Yousef DO, Marians KJ. DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex. J Biol Chem. 1996;271(42):26424–26429.
   PubMed Web of Science ®Google Scholar
• Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A, Zhao X. Quinolones: action and resistance updated. Curr Top Med Chem. 2009;9(11):981–998.
   PubMed Web of Science ®Google Scholar
• Wohlkonig A, Chan PF, Fosberry AP, et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010;17(9):1152–1153.
   PubMed Web of Science ®Google Scholar
• Drlica K, Zhao X. Bacterial death from treatment with fluoroquinolones and other lethal stressors. Expert Rev Anti Infect Ther. 2021;19(5):601–618.
   PubMed Web of Science ®Google Scholar
• Zhao X, Xu C, Domagala J, Drlica K. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci. 1997;94(25):13991–13996.
   PubMed Web of Science ®Google Scholar
• Hong Y, Li Q, Gao Q, et al. Reactive oxygen species play a dominant role in all pathways of rapid quinolone-mediated killing. J Antimicrob Chemother. 2020;75(3):576–585.
   PubMed Web of Science ®Google Scholar
• Snyder M, Drlica K. DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolinic acid. J Mol Biol. 1979;131(2):287–302.
   PubMed Web of Science ®Google Scholar
• Chow RT, Dougherty TJ, Fraimow HS, Bellin EY, Miller MH. Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12. Antimicrob Agents Chemother. 1988;32(8):1113–1118.
   PubMed Web of Science ®Google Scholar
• Mustaev A, Malik M, Zhao X, et al. Fluoroquinolone-Gyrase-DNA Complexes. J Biol Chem. 2014;289(18):12300–12312.
   PubMed Web of Science ®Google Scholar
• Goss WA, Deitz WH, Cook TM. Mechanism of action of nalidixic acid on Escherichia coli.Ii. inhibition of deoxyribonucleic acid synthesis. J Bacteriol. 1965;89:1068–1074.
   PubMed Web of Science ®Google Scholar
• Chen CR, Malik M, Snyder M, Drlica K. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J Mol Biol. 1996;258(4):627–637.
   PubMed Web of Science ®Google Scholar
• Malik M, Hussain S, Drlica K. Effect of anaerobic growth on quinolone lethality with Escherichia coli. Antimicrob Agents Chemother. 2007;51(1):28–34.
   PubMed Web of Science ®Google Scholar
• Gutierrez A, Jain S, Bhargava P, Hamblin M, Lobritz MA, Collins JJ. Understanding and sensitizing density-dependent persistence to quinolone antibiotics. Mol Cell. 2017;68(6):1147–1154.e1143.
   PubMed Web of Science ®Google Scholar
• Wu X, Wang X, Drlica K, Zhao X. A toxin-antitoxin module in Bacillus subtilis can both mitigate and amplify effects of lethal stress. PLoS One. 2011;6(8):e23909.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu X, Qu Y, Wang X, Li L, Zhao X. Inhibitors of reactive oxygen species accumulation delay and/or reduce the lethality of several antistaphylococcal agents. Antimicrob Agents Chemother. 2012;56(11):6048–6050.
   PubMed Web of Science ®Google Scholar
• Organization WH. Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2020. 2020.
   Google Scholar
• Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett. 2004;230(1):13–18.
   PubMed Web of Science ®Google Scholar
• Keren I, Shah D, Spoering A, Kaldalu N, Lewis K. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J Bacteriol. 2004;186(24):8172–8180.
   PubMed Web of Science ®Google Scholar
• Shah D, Zhang Z, Khodursky A, Kaldalu N, Kurg K, Lewis K. Persisters: a distinct physiological state of E. coli. BMC Microbiol. 2006;6:53.
   PubMed Web of Science ®Google Scholar
• Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol. 2007;5(1):48–56.
   PubMed Web of Science ®Google Scholar
• Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41(Suppl 2):S120–126.
   PubMed Web of Science ®Google Scholar
• Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. Prevalence in the United States of aac(6’)-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother. 2006;50(11):3953–3955.
   PubMed Web of Science ®Google Scholar
• Poole K. Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria. Antimicrob Agents Chemother. 2000;44(10):2595–2599.
   PubMed Web of Science ®Google Scholar
• Poole K. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother. 2000;44(9):2233–2241.
   PubMed Web of Science ®Google Scholar
• Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother. 2009;53(1):235–241.
   PubMed Web of Science ®Google Scholar
• Vázquez X, Fernández J, Hernáez S, Rodicio R, Rodicio MR. Plasmid-Mediated Quinolone Resistance (PMQR) in two clinical strains of Salmonella enterica serovar corvallis. Microorganisms. 2022;10(3):579.
   PubMed Web of Science ®Google Scholar
• Hopkins KL, Davies RH, Threlfall EJ. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents. 2005;25(5):358–373.
   PubMed Web of Science ®Google Scholar
• Price LB, Vogler A, Pearson T, Busch JD, Schupp JM, Keim P. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob Agents Chemother. 2003;47(7):2362–2365.
   PubMed Web of Science ®Google Scholar
• Redgrave LS, Sutton SB, Webber MA, Piddock LJV. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014;22(8):438–445.
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Igarashi M, Morimoto Y, Baba T, Umekita M, Akamatsu Y. Curing bacteria of antibiotic resistance: reverse antibiotics, a novel class of antibiotics in nature. Int J Antimicrob Agents. 2012;39(6):478–485.
   PubMed Web of Science ®Google Scholar
• Hooper DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb Perspect Med. 2016;6(9):a025320.
   PubMed Web of Science ®Google Scholar
• Lee S, Hinz A, Bauerle E, et al. Targeting a bacterial stress response to enhance antibiotic action. Proc Natl Acad Sci. 2009;106(34):14570–14575.
   PubMed Web of Science ®Google Scholar
• McMurry LM, Oethinger M, Levy SB. Overexpression of marA, soxS, or acrAB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli. FEMS Microbiol Lett. 1998;166(2):305–309.
   PubMed Web of Science ®Google Scholar
• Goldman JD, White DG, Levy SB. Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones. Antimicrob Agents Chemother. 1996;40(5):1266–1269.
   PubMed Web of Science ®Google Scholar
• Correia S, Poeta P, Hébraud M, Capelo JL, Igrejas G. Mechanisms of quinolone action and resistance: where do we stand? J Med Microbiol. 2017;66(5):551–559.
   PubMed Web of Science ®Google Scholar
• Hooper DC, Wolfson JS, Souza KS, Tung C, McHugh GL, Swartz MN. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother. 1986;29(4):639–644.
   PubMed Web of Science ®Google Scholar
• Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev. 2009;22(4):664–689.
   PubMed Web of Science ®Google Scholar
• Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci U S A. 2002;99(8):5638–5642.
   PubMed Web of Science ®Google Scholar
• Vetting MW, Hegde SS, Wang M, Jacoby GA, Hooper DC, Blanchard JS. Structure of QnrB1, a plasmid-mediated fluoroquinolone resistance factor. J Biol Chem. 2011;286(28):25265–25273.
   PubMed Web of Science ®Google Scholar
• Sánchez MB, Hernández A, Rodríguez-Martínez JM, Martínez-Martínez L, Martínez JL. Predictive analysis of transmissible quinolone resistance indicates Stenotrophomonas maltophilia as a potential source of a novel family of Qnr determinants. BMC Microbiol. 2008;8(1):148.
   PubMedGoogle Scholar
• Vetting MW, Park CH, Hegde SS, Jacoby GA, Hooper DC, Blanchard JS. Mechanistic and structural analysis of aminoglycoside N -acetyltransferase AAC(6′)-Ib and its bifunctional, fluoroquinolone-active AAC(6′)-Ib-cr variant. Biochemistry. 2008;47(37):9825–9835.
   PubMed Web of Science ®Google Scholar
• Aldred KJ, McPherson SA, Turnbough CL, Kerns RJ, Osheroff N. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res. 2013;41(8):4628–4639.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang H, Ning J, et al. The nature and epidemiology of OqxAB, a multidrug efflux pump. Antimicrob Resist Infect Control. 2019;8:44.
   PubMed Web of Science ®Google Scholar
• Kowalczykowski SC, Dixon DA, Eggleston AK, Lauder SD, Rehrauer WM. Biochemistry of homologous recombination in Escherichia coli. Microbiol Rev. 1994;58(3):401–465.
   PubMedGoogle Scholar
• Courcelle J, Khodursky A, Peter B, Brown PO, Hanawalt PC. Comparative gene expression profiles following UV exposure in wild-type and SOS-deficient Escherichia coli. Genetics. 2001;158(1):41–64.
   PubMed Web of Science ®Google Scholar
• Fernández De Henestrosa AR, Ogi T, Aoyagi S, et al. Identification of additional genes belonging to the LexA regulon in Escherichia coli. Mol Microbiol. 2000;35(6):1560–1572.
   PubMed Web of Science ®Google Scholar
• Friedberg EC, Walker GC, Siede W, Wood RD, Schultz RA, Ellenberger T. DNA Repair and Mutagenesis. Washington, DC, USA: ASM Press; 2005.
   Google Scholar
• Radman M. SOS repair hypothesis: phenomenology of an inducible DNA repair which is accompanied by mutagenesis. Basic Life Sci. 1975;5A:355–367.
   PubMedGoogle Scholar
• Theodore A, Lewis K, Vulic M. Tolerance of Escherichia coli to fluoroquinolone antibiotics depends on specific components of the SOS response pathway. Genetics. 2013;195(4):1265–1276.
   PubMed Web of Science ®Google Scholar
• Yamanaka T, Toyoshiba H, Sone H, Parham FM, Portier CJ. The TAO-Gen algorithm for identifying gene interaction networks with application to SOS repair in E. coli. Environ Health Perspect. 2004;112(16):1614–1621.
   PubMed Web of Science ®Google Scholar
• Feliciello I, Zahradka D, Zahradka K, Ivanković S, Puc N, Đermić D. RecF, UvrD, RecX and RecN proteins suppress DNA degradation at DNA double-strand breaks in Escherichia coli. Biochimie. 2018;148:116–126.
   PubMed Web of Science ®Google Scholar
• Górecka KM, Krepl M, Szlachcic A, Poznański J, Šponer J, Nowotny M. RuvC uses dynamic probing of the Holliday junction to achieve sequence specificity and efficient resolution. Nat Commun. 2019;10(1):4102.
   PubMedGoogle Scholar
• Smirnova GV, Tyulenev AV, Muzyka NG, Peters MA, Oktyabrsky ON. Ciprofloxacin provokes SOS-dependent changes in respiration and membrane potential and causes alterations in the redox status of Escherichia coli. Res Microbiol. 2017;168(1):64–73.
   PubMed Web of Science ®Google Scholar
• Andriole CL, Andriole VT. Are all quinolones created equal. Mediguide Infect Dis. 2002;21:1–5.
   Google Scholar
• Iannini PB, Niederman MS, Andriole VT. Treatment of respiratory infections with quinolones. In: The Quinolones. Elsevier; 2000:255–284.
   Google Scholar
• Weigelt J, Brasel K, Faro S. Use of quinolones in surgery and obstetrics and gynecology. In: The quinolones. Elsevier; 2000:285–301.
   Google Scholar
• DiCarlo RP, Martin DH. Use of the quinolones in sexually transmitted diseases. In: The quinolones. Elsevier; 2000:227–254.
   Google Scholar
• Nicolle LE. Use of quinolones in urinary tract infection and prostatitis. In: The Quinolones. Elsevier; 2000:203–225.
   Google Scholar
• Hamer DH, Gorbach SL. Use of the quinolones for treatment and prophylaxis of bacterial gastrointestinal infections. In: The quinolones. Elsevier; 2000:303–323.
   Google Scholar
• Karchmer AW. Use of the quinolones in skin and skin structure (Osteomyelitis) and other infections. In: The Quinolones. Elsevier; 2000:371–395.
   Google Scholar